FDA to grant breakthrough drug status to Glaxo’s drisapersen
The Breakthrough Therapy designation has been granted by the regulator, after vetting the results from the Phase II Study (DMD114117), submitted in April at Cold Spring Harbor. The
Ionis Pharmaceuticals has entered a licence agreement granting global pharmaceutical company Recordati exclusive rights to develop and commercialise zilganersen to treat Alexander disease (AxD) in countries outside the US.